Phase II trial results in people living with obesity or overweight
Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas
Tackling NCDs through innovation AND collaboration
Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them
The liver and its vital connection to our overall health
How health of the liver impacts our interconnected cardiovascular, renal, metabolic system and suffering and can have several comorbidities like obesity.
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with both empagliflozin and linagliptin is appropriate (US).
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults, used in monotherapy (if metformin is not tolerated or contraindicated) or in combination therapy.
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with metformin does not lead to sufficient control or when patients are treated with trajenta® (linagliptin) and metformin.
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with metformin does not lead to sufficient control or when patients are treated with jardiance® (empagliflozin) and metformin.
Oct. 2, 2023: Join us in London, or virtually, to learn more about our patient-centric approach to innovation, advancing pipeline and partnering approach.